Last reviewed · How we verify
NCT03910803
Treatment of Moderate Hidradenitis Suppurativa
Phase 2 trial testing Brodalumab in Hidradenitis Suppurativa in 20 participants. Status unknown.
1 December 2019
Quick facts
| Lead sponsor | Florida Academic Dermatology Centers |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 May 2019 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 May 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Brodalumab (BRODALUMAB) — full drug profile →
Conditions studied
- Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →
Sponsor
Florida Academic Dermatology Centers
Who can join
18 and older, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will be conducted over 24 weeks on active therapy followed by a four-week observational visit. The total length of the study will be 28 weeks. Study visits will occur at Screening, Baseline (Week 0), Weeks 4, 8, 12, 16, 20, 24 followed by an observational visit. Additionally, all subjects will be contacted by phone 1 week following the Baseline visit to ensure daily pain assessments are being recorded. If any signs or symptoms are reported at the time of the call, an unscheduled study visit will be conducted to assess whether an infection is present. Adverse events will be collected throughout the study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.
Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T. · · 2025 · cited 8× · PMID 39604776 · DOI 10.1007/s40259-024-00687-w
Verify or expand the search:
- PubMed search for NCT03910803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Brodalumab
Trials testing the same drug.
- NCT04305327 — Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis · Phase 3 · terminated
- NCT04306315 — Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and · Phase 4 · completed
- NCT05132231 — Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Wor · active not recruiting
- NCT04979520 — Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa · EARLY_PHASE1 · completed
- NCT04533737 — Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Respons · Phase 4 · terminated
Other recruiting trials for Hidradenitis Suppurativa
Currently open trials in the same condition.
- NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
- NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
- NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
- NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
- NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03910803 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Florida Academic Dermatology Centers
- Last refreshed: 10 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03910803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing